Burotto M, Zvirbule Z, Mochalova A, Runglodvatana Y, et al. IMscin001 Part 2: A randomised phase III, open-label, multicentre study examining the pharmacokinetics (PK), efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous in previously treated locally advanced or metastatic non- Ann Oncol 2023 May 31:S0923-7534(23)00694-4. doi: 10.1016/j.annonc.2023.
PMID: 37268157